946568-34-9

Basic information

• Product Name: [1-(4,4'-dimethoxytrityl)]-3-hexadecylglycerol
• Synonyms: [1-(4,4'-dimethoxytrityl)]-3-hexadecylglycerol
• CAS NO: 946568-34-9
• Molecular Weight: 618.898
• Mol File: 946568-34-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: [1-(4,4'-dimethoxytrityl)]-3-hexadecylglycerol(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4,4'-dimethoxytrityl)]-3-hexadecylglycerol(946568-34-9)
• EPA Substance Registry System: [1-(4,4'-dimethoxytrityl)]-3-hexadecylglycerol(946568-34-9)

Safety Data

• Hazardous Substances Data: 946568-34-9(Hazardous Substances Data)

Upstream product

• 112-82-3 hexadecanyl bromide 
• 89496-73-1 4-(n-hexadecyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 6145-69-3 3-(hexadecyloxy)-1,2-propanediol 
• 40615-36-9 4,4'-dimethoxytrityl chloride 

Downstream Products

• 260430-24-8 [1-(4,4'-dimethoxytrityl)]-2-succinyl-3-hexadecylglycerol 

Relevant articles and documents

NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT

The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.